A human ICAM-1 antibody isolated by a function-first approach has potent macrophage-dependent antimyeloma activity in vivo.

@article{Veitonmki2013AHI,
  title={A human ICAM-1 antibody isolated by a function-first approach has potent macrophage-dependent antimyeloma activity in vivo.},
  author={Niina Veitonm{\"a}ki and Markus Hansson and Fenghuang Zhan and Annika Sundberg and Tobias L{\"o}fstedt and Anne Ljungars and Zhan-Chun Li and Titti Martinsson-Niskanen and Ming Zeng and Ye Yang and Linda Danielsson and Mathilda Kovacek and Andrea Lundqvist and Linda Maria M{\aa}rtensson and Ingrid Teige and Guido Tricot and Bj{\"o}rn L. Frend{\'e}us},
  journal={Cancer cell},
  year={2013},
  volume={23 4},
  pages={
          502-15
        }
}
We isolated a tumor B-cell-targeting antibody, BI-505, from a highly diversified human phage-antibody library, using a pioneering "function-first" approach involving screening for (1) specificity for a tumor B cell surface receptor, (2) induction of tumor programmed cell death, and (3) enhanced in vivo antitumor activity compared to currently used treatments. BI-505 bound to intercellular adhesion molecule-1, identifying a previously unrecognized role for this receptor as a therapeutic target… CONTINUE READING
BETA

From This Paper

Figures, tables, and topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 26 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 44 REFERENCES

Similar Papers

Loading similar papers…